November 20, 2017- Interviewed by Steven E. Greer, MD
We interviewed Emory University oncologist Suresh S. Ramalingam, M.D. about his NEJM paper on third-generation oral EGFR inhibitor Tagrisso (osimertinib) by AstraZeneca.
November 20, 2017- Interviewed by Steven E. Greer, MD
We interviewed Emory University oncologist Suresh S. Ramalingam, M.D. about his NEJM paper on third-generation oral EGFR inhibitor Tagrisso (osimertinib) by AstraZeneca.